Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN +7.37%24 3-Year EBITDA Growth Rate is 23.50% as of Dec. 2025, which is 4% above its 10-year median of 22.55. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 69.48% on this metric.
During the past 12 months, Anbio Biotechnology's average EBITDA Per Share Growth Rate was 193.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Anbio Biotechnology was 23.50% per year. The lowest was 21.60% per year. And the median was 22.55% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Anbio Biotechnology 3-Year EBITDA Growth Rate Related Terms
NNNN vs SMTI, EMBC, OSUR: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.50% mean?
Anbio Biotechnology (NNNN) has a 3-Year EBITDA Growth Rate of 23.50% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anbio Biotechnology and its competitors. This is near median its historical median of 22.55. Over the past decade, Anbio Biotechnology's 3-Year EBITDA Growth Rate has ranged from 21.60 to 23.50. According to the industry distribution chart, Anbio Biotechnology ranks #210 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Anbio Biotechnology's 3-Year EBITDA Growth Rate too high?
Anbio Biotechnology's current 3-Year EBITDA Growth Rate of 23.50% is near median its 10-year median of 22.55. Over the past 10 years, this metric has ranged from a low of 21.60 to a high of 23.50. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Anbio Biotechnology's value of 23.50% is 190.1% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #210 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's 3-Year EBITDA Growth Rate compare to SMTI and EMBC?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #210 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Anbio Biotechnology in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Anbio Biotechnology's value of 23.50% is 190.1% above this benchmark. Historically, Anbio Biotechnology's own 3-Year EBITDA Growth Rate has ranged from 21.60 to 23.50 over the past decade. While the company's 10-year median is 22.55 vs. the industry median of 8.10, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current 3-Year EBITDA Growth Rate of 23.50% is 190.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current 3-Year EBITDA Growth Rate is 23.50%, which is near median its own 10-year median of 22.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current 3-Year EBITDA Growth Rate of 23.50%. The current 3-Year EBITDA Growth Rate is 23.50%, which is near median its 10-year median of 22.55 and 190.1% above the Medical Devices & Instruments industry median of 8.10. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current 3-Year EBITDA Growth Rate is 23.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
